Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein
Rift Valley fever (RVF) is a viral hemorrhagic disease first discovered in Kenya in 1930. Numerous animal studies have demonstrated that protective immunity is acquired following RVF virus (RVFV) infection and that this correlates with acquisition of virus-neutralizing antibodies (nAbs) that target...
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Journal Article |
| Lenguaje: | Inglés |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://hdl.handle.net/10568/109976 |
Ejemplares similares: Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein
- Development of Rift Valley fever vaccine suitable for human and livestock use
- Mammalian expression of functional autologous red blood cell agglutination reagents for use in diagnostic assays
- Detection of Rift Valley fever virus interepidemic activity in some hotspot areas of Kenya by sentinel animal surveillance, 2009–2012
- Hyperendemicity of Rift Valley fever in Southwestern Uganda associated with the rapidly evolving lineage C viruses
- Taxonomy of the order Bunyavirales: update 2019
- 2021 Taxonomic update of phylum Negarnaviricota (Riboviria: Orthornavirae), including the large orders Bunyavirales and Mononegavirales